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Micro-RNAs (miRNAs) are small non-coding RNA molecules which 
provide a subtle layer of regulation to thou-
sands of cellular genes. The identification 
of virally encoded miRNAs added another 
layer of complexity to the dense interac-
tion between viruses and their natural 
hosts. While it has been shown that viral 
miRNAs can regulate both cellular and 
viral gene expression, target identification 
has been a difficult and cumbersome task. 
The immunoprecipitation of Argonaute 
(Ago)-protein containing RNA-induced 
silencing complexes (RISC) followed by 
microarray analysis (RIP-Chip) allows 
the identification of miRNA-targetomes 
at whole transcriptome level. We applied 
Ago2-based RIP-Chip to identify cellular 
transcripts targeted by Kaposi’s sarcoma-
associated herpesvirus (KSHV, n = 114), 
Epstein-Barr virus (EBV, n = 44) and cel-
lular miRNAs (n = 2,337) in six latently 
infected or stably transduced human 
B-cell lines. While RIP-Chip yields a 
plethora of high-confidence miRNA 
targets and provides a quantitative esti-
mate of miRNA function, additional 
biochemical methods like HITS-CLIP or 
PAR-CLIP and bioinformatic analysis are 
required to identify individual miRNA 
binding sites. Together, these methods 
will be useful to unravel the network of 
regulation exerted by both viral and cel-
lular miRNAs, thereby providing the 
basis for functional studies on miRNA-
mediated regulation of gene expression in 
herpesvirus infections.
The Herpesvirus Family
Herpesviruses are large double stranded 
DNA viruses which have evolved with 
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their animal and human hosts over mil-
lions and millions of years. More than 
120 different herpesviruses have so far 
been identified in mammals, birds, rep-
tiles and even invertebrates (e.g., oysters). 
They can be divided into three subfami-
lies (α-, β- and γ-herpesviruses) based 
on sequence homologies and biological 
features.1 A unique feature of all herpesvi-
ruses is their ability to establish a life-long 
infection. Thus, once infected the virus is 
maintained for life. The virus persists in 
the nucleus of infected cells as an extra-
chromosomal episome with a stable copy-
number in a state termed ‘latency’. During 
this phase only a few viral proteins are 
expressed, which mainly contribute to 
maintenance of latency and immune eva-
sion.2 Triggered by specific endogenous 
or exogenous factors, like stress, immune 
suppression, UV-light or hormones, the 
virus can reactivate into the lytic stage of 
infection. This results in recurrent pro-
duction and release of infectious virus 
particles finally resulting in death of the 
infected cell.
To date, eight human herpesviruses 
(HHV-1 to HHV-8) have been discov-
ered. Two of them, KSHV (Kaposi’s sar-
coma associated Herpesvirus, HHV-8) 
and EBV (Epstein-Barr virus, HHV-4), 
are γ-herpesviruses that have oncogenic 
potential and are able to infect B-cells. 
In immunocompromised individuals, 
infection with EBV or KSHV can result 
in lymphoproliferative disorders.3 KSHV 
is involved in the development of several 
human tumors, including Kaposi’s sar-
coma, primary effusion lymphoma and 
multicentric Castleman’s disease.4,5 In 
most infected cells the virus resides in 
the latent form, and during this phase of 
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carcinomas, as well as posttransplant 
lymphoproliferative disease (PTLD). 
EBV latent gene expression in various 
EBV-associated malignancies and EBV-
derived cell lines has led to the identifica-
tion of three different and distinct latency 
programs. These latency programs are 
the result of differential promoter activ-
ity and are influenced by host cell factors. 
EBV encodes at least 25 miRNAs, which 
are located in two primary transcripts, 
the BHRF1 transcript which also encodes 
the BHRF1 ORF, and the BamHI A 
rightward transcripts (BARTs). The 
BARTs contain two clusters of miRNAs, 
which have been termed Cluster 1 and 
Cluster 2. Among different cell lines, the 
miRNAs of EBV are expressed at dra-
matically differing levels. Interestingly, 
the prototype B95.8 strain of EBV has 
lost more than half of the viral miRNAs 
during cell culture passages indicating 
that expression of these viral miRNAs 
may be of disadvantage for the virus in 
cell culture.21 Until recently, only three 
cellular targets for EBV encoded miR-
NAs including the chemokine CXCL-11, 
the p53-regulated modulator of apoptosis 
(PUMA) and the immune ligand MICB, 
were known.13,22,23 In addition there are 
several viral genes known to be regulated 
by EBV-encoded miRNAs. These are, for 
example, the viral Polymerase BALF5 and 
the latent membrane protein LMP2A.24,25
All attempts to identify targets for 
γ-herpesviral miRNAs either relied only 
on bioinformatic predictions, or employed 
microarray analysis on total RNA to iden-
tify viral miRNA targets, based on the 
very modest effect of miRNAs on the 
RNA stability of their targets. While these 
approaches have led to successful identifi-
cation of a few cellular and viral targets 
for these viral miRNAs, the experimental 
work is cumbersome and full of difficul-
ties. Bioinformatic approaches are ham-
pered by the fact that miRNAs require 
only limited complementarity to their 
binding sites, as even a complete SEED 
complementarity of seven nucleotides is 
not always essential. Similar, the microar-
ray expression profiling analysis on total 
RNA also has major limitations: First, 
transcript levels of miRNA targets are not 
necessarily affected if regulation occurs 
predominantly by translational repression. 
little sequence and positional conserva-
tion which probably reflects the great 
flexibility of these viral modulators. The 
finding that both KSHV and EBV regu-
late hsa-miR-155 targets may indicate that 
this is not necessarily the same for the tar-
gets of their miRNAs. Interestingly, the 
Mandelboim lab identified the activating 
natural killer cell ligand MICB, which 
is induced in cells upon infection result-
ing in NK-cell killing of the infected cell, 
to be targeted by both KSHV and EBV 
as well as human cytomegalovirus,13,14 
thereby highlighting the role of this pro-
tein in antiviral defense against herpes-
viruses in general. Interestingly, none of 
these viruses targeted the closely related 
NK-cell activating ligand MICA, while 
both MICA and MICB are also heavily 
regulated by cellular miRNAs.
Targets of miRNAs 
From Herpesviruses
In the last three years, a series of papers 
were published in which single cellu-
lar targets of KSHV miRNAs were pre-
sented. For example, in 2007 the Renne 
lab identified THBS1, a major regulator 
of cell adhesion, migration and angio-
genesis, to be targeted by KSHV-encoded 
miRNAs which may contribute to the 
pathogenesis of Kaposi sarcoma.15 Other 
targets included the transcription factors 
CEB/P and MAF, an inhibitor of NFκB 
activation (IKBA), RBL2, an inhibitor 
of DNA-methylases, whose regulation by 
KSHV miRNAs had an effect on epigen-
etic regulation of viral latency, and the 
cyclin dependent kinase (CDK)-inhibitor 
p21.16-20 In addition, also one viral target 
was identified, the transcriptional acti-
vator RTA (KSHV ORF50), which is 
the master regulator of lytic reactivation 
in KSHV. In summary, until recently 
approximately 25 cellular and viral targets 
of KSHV miRNAs had been identified.
Little is still known about the func-
tion of viral miRNAs in the context of 
EBV infection. EBV is a very successful 
pathogen that infects >90% of all adult 
humans worldwide. It has been linked 
to various human malignancies includ-
ing Burkitt’s, Hodgkin’s, NK/T-cell, 
peripheral T-cell and post-transplant 
lymphomas, nasopharyngeal and gastric 
infection only four viral proteins (of at 
least 89) are expressed via a set of differen-
tially spliced transcripts from a common 
locus called “latency associated region” 
(LAR), including Kaposin, an oncogenic 
protein, v-FLIP, a viral homologue of 
the cellular FLICE-inhibitory protein, 
v-Cyclin, a viral homologue of cellular 
D-type-cyclins and LANA (Latency asso-
ciated nuclear antigen).6
Herpesviruses and microRNAs
As not all of the drastic changes that a 
cell or a tissue undergoes upon latent 
KSHV infection can be explained by the 
expression of these four proteins, it was 
an interesting discovery made by three 
independent groups in 2005 in parallel, 
that a set of 12 conserved pre-miRNAs 
is expressed from the KSHV LAR-locus 
during virus latency.7-9
Micro-RNAs (miRNAs) are endog-
enous, 21–23 nucleotide long, non-coding 
RNA molecules that regulate protein-cod-
ing gene expression in plants and animals 
via the RNA silencing machinery. Human 
cells express at least approximately 700 
miRNAs which are involved in the regu-
lation of virtually every biological path-
way. It was intriguing to speculate that 
viral miRNAs regulate both cellular and 
viral gene expression to support the estab-
lishment and maintenance of latency, as 
well as lytic reactivation. Interestingly, 
it was soon identified by two different 
groups in parallel that KSHV encodes an 
orthologue (or in our opinion rather an 
analogue) of cellular miR-155,10,11 an evo-
lutionary conserved miRNA upregulated 
in several types of cancer. This resulted in 
the identification of 16 cellular transcripts 
targeted by both kshv-K12-11 and hsa-
miR-155. While these targets are known 
to play important roles in B-cell func-
tion, innate immunity, apoptosis and cell 
cycle control, the biological effects of their 
regulation by kshv-miR-K12-11 remain 
to be elucidated. Interestingly, it was sub-
sequently discovered that EBV infection 
resulted in a NFκB-dependent induction 
of hsa-miR-155 in human B-cells,12 indi-
cating that miRNA-mediated downregu-
lation of hsa-miR-155 targets seems to be in 
favor of these two human γ-herpesviruses. 
In general, viral miRNAs show only very 
©2011 Landes Bioscience.
Do not distribute.
32 RNA Biology Volume 8 issue 1
and cellular miRNAs (n = 2,337). In 
short, RISC-immunoprecipitation with 
the AGO2-specific antibody resulted 
in a ~1,000-fold enrichment of cellular 
miRNAs (e.g., let7a or miR-16) com-
pared to an unspecific control antibody. 
About 50% of cellular miRNAs could 
be recovered indicating that at least half 
of all cellular miRNAs in human B-cells 
are incorporated into AGO2-containing 
RISC-complexes. Two known targets of 
cellular miRNAs (CCNE1 and MICA) 
were typically enriched by ~8-fold as 
determined by RT-PCR. We then used 
microarray analysis (Affymetrix Gene ST 
1.0 arrays) to identify both cellular and 
viral miRNA targets. Enrichment of tran-
scripts in the Ago2-IP vs. control (BrdU-IP 
or total RNA) ranged up to ~40-fold with 
up to ~1,400 transcripts showing >2-fold 
enrichment. We analyzed the enrichment 
profiles of 11,714 protein coding genes for 
monoclonal antibody followed by RNA-
extraction and subsequent quantification 
of mRNAs on microarrays, has recently 
been utilized to identify mRNAs that 
are associated with the RNA-silencing 
machinery and therefore are targets of cel-
lular miRNAs.26-31 First approaches used 
cell lines which expressed c-myc-tagged 
Ago2, and used a Myc-specific antibody 
to pull down miRNA/targets complexes. 
Recently, the Meister lab developed a 
highly specific monoclonal antibody to 
human Argoaute2 (α-hAgo2; 11A9). We 
now used this monoclonal antibody and 
established an Ago2-based RIP-Chip 
protocol to identify transcripts targeted 
by KSHV, EBV and cellular miRNAs 
in six latently infected or stably trans-
duced human B-cell lines (Fig. 1).32 
This resulted in the identification of a 
large number of high-confidence targets 
for KSHV (n = 114) and EBV (n = 44) 
Second, since the observed effects are 
usually only very small and mostly do 
not exceed 2-fold many bona fide targets 
are missed. Finally, secondary targets are 
difficult to distinguish as a multitude of 
transcripts may be affected due to second-
ary effects. As even sophisticated bioin-
formatic approaches have not been able to 
solve these problems in a satisfactory way, 
the identification of viral miRNA targets 
was based on a trial-and-error strategy 
and required a high number of genes to be 
screened, and therefore was inadmissibly 
labor-intensive.
RISC-immunoprecIpitation  
Allows the Identification  
of miRNA Targets
RIP-Chip analysis, the immunoprecipi-
tation of RNA-induced silencing com-
plexes (RISC) with an Argonaute-specific 
Figure 1. RiP-Chip workflow. Protein-G sepharose beads are coated with a monoclonal antibody to Ago2 or a control antibody (anti-BrdU). Cells 
are lysed, cleared by centrifugation and lysates stored at -80°C until immunoprecipitation (iP). Following the iP, sepharose beads are lysed and RNA 
molecules are recovered using Qiazol reagent. Most importantly, the efficiency of every iP is controlled by quantitative PCR for an abundant cellular 
miRNA (e.g., let7a or miR-16). in addition, the capture efficiency of the iP is determined by comparing miRNA levels between the Ago2-iP and total RNA 
(=input). in human cells, we generally observed a capture efficiency of ~50% and an enrichment of let7a of ~1,000-fold.
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next-generation sequencing (CLIP-Seq) 
now provide access to miRNA binding 
sites at whole transcriptome level.38,39 As 
these methods are most likely not quan-
titative due to cloning and sequencing 
biases, a combination of RIP-Chip confi-
dently identify their targets. On the other 
hand, these data also demonstrate that 
RIP-Chip analysis offers a quantitative 
estimate of miRNA function. Therefore, 
the extent of enrichment observed in the 
RISC-IP may serve to identify the most 
strongly and relevantly regulated targets.
In contrast to other methods, RIP-
Chip analysis is based on positive selec-
tion of miRNA targets. It is important to 
note, however, that a lack of enrichment 
does not exclude a transcript to be tar-
geted by miRNAs. This may be for sev-
eral reasons. First, some genes may simply 
be expressed below the detection limit of 
the arrays and may thus escape detection. 
In addition, targets showing as little as 
1.2-fold enrichment still contained a sig-
nificant above-average numbers of pre-
dicted miRNA binding sites. Therefore, 
already very little enrichment is compati-
ble with miRNA-mediated regulation. We 
restricted our analysis to the most strongly 
enriched targets, i.e., >3-fold. Therefore, 
we are quite certain that many additional 
targets can be found in our set of data 
when less stringent criteria are employed. 
While only three of the published KSHV 
miRNA targets fulfilled our criteria as 
miRNA targets (PIK3CA, SLA and 
NFKBIA), we observed an enrichment of 
>1.5-fold for approximately 60% of the 
published KSHV and EBV miRNA tar-
gets. For example, MICB was significantly 
stronger enriched in the Ago2-IPs of both 
KSHV- and EBV-infected cells as identi-
fied by microarray analysis and confirmed 
by quantitative PCR.
Conclusions
While RIP-Chip analyses are able to iden-
tify high-confidence miRNA targets and 
provide limited information about their 
biological relevance, the determination 
of the actual binding sites still remains a 
cumbersome task. Using the RNAhybrid 
algorithm, we were only able to confirm 
about 50% of the predicted binding sites 
in our KSHV and EBV miRNA targets. 
miRNAs and the Half-Life  
of Transcripts
It has been a long standing debate to what 
extent miRNAs regulate the stability of 
their targets. So far all available data rely 
on measurements of changes in total RNA 
thereby reflecting the changes in RNA sta-
bility.34,35 Also these studies only showed a 
very minor effect of cellular miRNAs on 
transcript levels hardly exceeding 2-fold, a 
main concept commonly pursued to iden-
tify viral miRNA targets still is to screen 
for potential effects on total RNA levels 
by microarray analysis. We applied a novel 
approach we recently developed, now 
termed 4sU-tagging, to directly measure 
RNA half-lives and not their impact on 
total RNA levels. This approach is based 
on metabolic tagging of nascent RNA 
(e.g., for 60 min) by adding 4-thiouri-
dine (4sU) to the cell culture medium 
followed by isolation of total RNA, 
thiol-specific biotinylation of 4sU-tagged 
nascent RNA and separation of total cel-
lular RNA into nascent and pre-existing 
untagged RNA using streptavidin-coated 
magnetic beads.36,37 RNA half-lives can 
then be determined based on nascent/
total, nascent/untagged or untagged/
total RNA ratios. Thus, we determined 
RNA half-lives for >10,000 transcripts in 
4 of the 6 human B-cell lines to investi-
gate the effect of both cellular and viral 
miRNA on RNA stability. We found a 
small, however highly significant negative 
correlation in between median RNA half-
life and enrichment in the Ago2-IP (p < 
10-16), reflecting recruitment of transcript 
to Ago2-RISC-complexes. For KSHV 
miRNA targets, this was exclusively seen 
in the KSHV positive cell line BCBL-1 
indicating that both viral and cellular 
miRNAs have a small, however significant 
impact on target RNA stability resulting 
in a mean reduction in RNA half-life of 
~10–15%. Although this does not exclude 
that individual transcripts are destabilized 
in a more pronounced way it indicates 
that the effect of miRNAs on target RNA 
stability is generally too small to be effi-
ciently utilized to able to confirm about 
50% of the predicted binding sites in our 
KSHV and EBV miRNA targets. Recent 
advances in UV-cross-linking technologies 
(HITS-CLIP and PAR-CLIP) followed by 
the presence of binding sites for 44 known 
B-cell specific miRNAs. Interestingly, 
transcripts, enriched as little as 1.2-fold, 
already showed highly significant over-
representation of predicted miRNA tar-
get site using either PITA or RNAhybrid. 
Binding sites of cellular miRNAs were 
particularly overrepresented in tran-
script 3'-UTRs (p = 6.2 x 10-63) and cod-
ing sequences (p = 2.010-27) but not in 
5'-UTRs (p = 8.9 x 10-3). Therefore, we 
considered 2.337 transcripts significantly 
enriched >1.2-fold across all six cell lines 
to be targets of cellular miRNAs. Targets 
of KSHV and EBV miRNAs were defined 
by their property to be enriched to a sub-
stantially greater extent (>3-fold) in the 
infected cell lines (BCBL-1 and Jijoye) 
compared to two control cell lines. This 
resulted in 114 targets of KSHV and 44 of 
EBV miRNAs, and the analysis revealed 
that there was a significant enrichment of 
binding sites for viral miRNAs on these 
transcripts. The substantially greater 
number of KSHV miRNA targets simply 
reflects the slightly greater mean enrich-
ment in BCBL-1 than in Jijoye which we 
did not compensate for by applying addi-
tional normalization steps. This approach 
yielded high confidence targets of viral 
miRNAs. First, 18/19 (95%) of the viral 
miRNA targets were confirmed by quan-
titative PCR. We then randomly picked 
6 putative KSHV miRNA targets and 
performed dual luciferase assays. Four tar-
gets revealed regulation via their 3'-UTR, 
two via binding sites located within cod-
ing sequences. Interestingly, we predomi-
nantly identified binding sites for the 
most prominent KSHV miRNAs showing 
expression of >1,000 copies/cell as deter-
mined by quantitative PCR. In addition, 
we validated two genes known to gov-
ern cellular transport pathways, namely 
importin 7 (IPO7) and transporter of the 
mitochondrial out membrane 22 (TOM22) 
as EBV miRNA targets. While regula-
tion of TOM22 may help EBV to prevent 
BAX-induced apoptosis downregulation 
of IPO7 may be involved in modulating 
cytokine signaling in EBV infected cells. 
The recent finding that EBV may modu-
late gene expression also in uninfected 
cells via secretion of viral miRNAs within 
exosomes is an interesting concept to be 
tested in further studies.33
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Recent advances in UV-cross-linking tech-
nologies (HITS-CLIP and PAR-CLIP) 
followed by next-generation sequenc-
ing (CLIP-Seq) now provide access to 
miRNA binding sites at whole transcrip-
tome level.6,15 As these methods are most 
likely not quantitative due to cloning and 
sequencing biases, a combination of RIP-
Chip and CLIP-seq appears to be the way 
of choice to continue, which will soon 
result in the identification of hundreds of 
binding sites for both cellular and viral 
miRNAs. While this will dramatically 
improve our understanding in the biology 
of miRNA-mediated regulation of gene 
expression, the biological consequences 
and the relevance of their regulation for 
example at different stages of the virus life 
cycle remain to be elucidated.
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